Editorial response: U.S. food and drug administration approval of ambisome (liposomal amphotericin b) for treatment of visceral leishmaniasis - Статья

бесплатно 0
4.5 141
The pathogenesis, clinical investigation, medical microbiology, diagnosis, immune mechanisms of diseases caused by infectious agents. Treatment of visceral leishmaniasis (VL) with the first licensed of an antileishmanial drug in the United States.


Заказать написание новой работы



Дисциплины научных работ



Хотите, перезвоним вам?